METFORMIN SAFE SINCE 1958 Cardiovascular benefits and anti ageing

METFORMIN SAFE SINCE 1958 Cardiovascular benefits and anti ageing

Will Metformin Become the First Anti-Aging Drug?

New studies appear almost daily revealing how metformin inhibits aging by boosting AMPK activity. Data on cancer risk reductions provide an even greater urgency for maturing individuals to reactivate their cellular AMPK.

Scientifically reviewed by: Dr. Tennoy V., MV, in October 2024. Written by: Raegan Linton. Cancer Protective Effects of Metformin (See article ) Metformin Prevents Cardiovascular Disease

Despite billions of dollars spent on drugs such as Crestor and Lipitor, cardiovascular disease remains the single biggest killer in America. While there are multiple causes of cardiovascular disease, most boil down to the development of atherosclerosis, or “hardening of the arteries.”

Atherosclerosis is promoted by factors such as oxidation of LDL cholesterol, accumulation of that oxidized fat in arterial walls, and damage to the endothelium, which is the thin layer of cells lining those arterial walls.²¹

Metformin is now known to prevent these early steps in atherosclerosis development.

One of the key ways it does this is by activating the metabolic regulator AMPK. By activating AMPK, metformin:

• Mitigates LDL oxidation and the resulting endothelial dysfunction, which slows the development of atherosclerosis.²¹

• Reduces the conversion of harmless immune system cells (monocytes) into fat-laden macrophages, an action that reduces their accumulation in vessel walls.²² It also increases cholesterol export out of those cells, while also suppressing the inflammatory stimulus they normally produce.^23,24

• Offers critical protection to endothelial cells that line coronary arteries, which supply blood to the heart muscle itself. Specifically, metformin enhances the resistance of endothelial cells to “fat poisoning,” the death of endothelial cells in the presence of high fat concentrations.²⁵ This is highly protective against heart attacks, which occur when coronary arteries, blocked by atherosclerotic plaques laden with fat and inflammatory cells, fail to provide enough blood to the hard-working heart muscle.

Metformin has also been shown to prevent the fragmentation of mitochondria in endothelial cells.²⁶ Such fragmentation is closely associated with the dysfunction of endothelial cells and is now considered an important precursor of atherosclerosis.²⁶

The results of these protective effects have been seen in numerous human studies. In one study, heart attack patients taking metformin had a significant 75% reduction in the risk of dying after 30 days, and a 68% reduction in their risk of dying 12 months after the attack.²⁷

Several studies have also demonstrated that metformin reduces the risk of heart attack, and is associated with reduction in stroke, atrial fibrillation (an arrhythmia), and death from all causes.²⁸

Finally, a 2016 study showed significant reductions in systolic (top number) blood pressure in nondiabetic people taking metformin. The largest reductions were seen in those having impaired glucose tolerance or obesity.²⁹

Obesity itself appears ready to yield to metformin treatment, as we’ll now see.

Full article link below

https://www.lifeextension.com/magazine/2017/4/metformin-slashes-cancer-risks?srsltid=AfmBOoppwbwjDHA8jBLjN8qMjMzEELPggj89UzSlW_tpwiVk4zkXYZIS